Respiratory disease is a huge global issue, with asthma and chronic obstructive pulmonary disease (COPD) affecting hundreds of millions globally. COPD was reported by the WHO as the third-leading...
Pharmaceuticals

Apr 12, 2023 | Published by Andrew Lee
Pharmaceuticals
Our Senior Consultant, Andrew Lee has written an article on ‘Making Inhaled Therapies Fit for the Future: Improving the Sustainability of Pressurised Metered Dose Inhalers’ for Innovations in Pharmaceutical Technology magazine.
The article investigates how pressured metered dose inhalers (pMDIs) have become the most popular treatment choice for patients suffering from common respiratory diseases such as asthma, despite pMDIs accounting for 3.9% of the NHS’s annual carbon emissions. Andrew looks at what options are available to improve the sustainability of the device in the future. You can read the full article here -
Ensure your business stays ahead of the competition by keeping up to date on the latest regulatory changes. Sign-up for our bi-monthly regulatory digest to have the latest information and insights served direct to your inbox.
Respiratory disease is a huge global issue, with asthma and chronic obstructive pulmonary disease (COPD) affecting hundreds of millions globally. COPD was reported by the WHO as the third-leading...
1 minute read
Smoking is one of the most efficient and effective methods of delivering a drug to the lungs; which is one of the reasons smoking provides such efficient and quick drug delivery is the way that the...
AIT (Association of Inhalation Toxicologists) was held at the AstraZeneca facility in Gothenburg, Sweden, in May. Day one opened with two-minute pitches from the ten exhibitors including ImmuONE,...